Key Highlights
- HAYA Therapeutics appoints Dr. Jordan Shin as Chief Medical Officer.
- Dr. Shin brings over a decade of experience in cardiovascular and lung translational medicine.
- He will lead the clinical development of HTX-001 for non-obstructive hypertrophic cardiomyopathy.
- Prior leadership roles at LEXEO Therapeutics and Renovacor, and academic tenure at Harvard Medical School.
Source: Business Wire
Notable Quotes
- “Dr. Shin’s strong background in translational research and clinical development will help us bring this and other important medicines to those in need.” — Samir Ounzain, Ph.D., Co-founder and CEO at HAYA Therapeutics
- “HAYA’s full-stack RNA-guided regulatory genome platform uniquely positions the company to make a significant impact on patients suffering from cardiovascular diseases.” — Jordan Shin, M.D., Ph.D., Chief Medical Officer at HAYA Therapeutics
SoHC's Take
Dr. Jordan Shin’s appointment as Chief Medical Officer marks a pivotal moment for HAYA Therapeutics. His wealth of experience in advancing genetic medicines, particularly in the cardiovascular space, will be instrumental in steering the company’s precision therapeutics towards clinical success. His track record with groundbreaking programs, like those at LEXEO Therapeutics, indicates a strategic alignment with HAYA’s innovative RNA-guided platform. As HAYA progresses its lead candidate, HTX-001, into clinical development, Dr. Shin’s leadership will be vital in transforming HAYA’s ambitious therapeutic goals into realities that benefit patients globally.
